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Fast Pathway Properties, introduction: The purpose of this study was to prospectively
compare the effects of complete and partial ablation of slow pathway function on the fast path-
way effective refractory period (ERP).
Methods and Results: The subjects were 20 patients (mean age 43 ± 13 years) with atrio-
ventricular nodal reentrant tachycardia (AVNRT), no structural heart disease, and easily
inducible AVNRT. Autonomic blockade was achieved with propranolol (0.2 mg/kg) and
atropine (0.04 mg/kg). After elimination of AVNRT and during autonomic blockade, the
presence of residual slow pathway function was determined by the presence of a single AV
nodal echo and/or dual AV nodal physiology. After autonomic blockade and before abla-
tion, the mean fast pathway ERP was 319 ± 44 msec and the mean slow pathway ERP was
251 ± 31 msec. After slow pathway ablation and during autonomic blockade, 7 patients had
residual slow pathway function and 13 did not. Complete loss of slow pathway function was
associated with a shortening of the fast pathway ERP from 334 ± 35 msec to 300 ± 62 msec
(P < 0.01), while the fast pathway ERP did not change significantly in patients with residual
slow pathway function (291 ± 29 msec vs 303 ± 38 msec, respectively; P = 0.08). A shorten-
ing of 30 msec or more in the fast pathway ERP was observed in 11 of 13 patients who did
not have residual slow pathway function, compared to 0 of 7 patients with residual slow
pathway function (P < 0.001).
Conclusion: Shortening of the fast pathway ERP after successful ablation of AVNRT is
dependent upon complete loss of slow pathway function. This observation is consistent with
electrotonic inhibition of the fast pathway by the slow pathway. (J Cardiovasc Electrophysiol,
Vol. 5, pp. 645-649, August 1994)
autonomic blockade, radiofrequency energy, paroxysmal supraventricular tachycardia
Introduction
Successful endpoints for elimination of atrio-
ventricular nodal reentrant tachycardia (AVNRT)
by radiofrequency catheter ablation of the slow
pathway consist of elimination of all slow path-
way function''2 or elimination of the induction
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of AVNRT with evidence of residual slow path-
way function.^" The fast pathway effective refrac-
tory period (ERP) has been observed to shorten
paradoxically after slow pathway ablation''5; how-
ever, the mechanism of this eflFect has been unclear.
No prior study has compared the effect of com-
plete and partial ablation of slow pathway func-
tion on the fast pathway ERP. Therefore, in an
attempt to elucidate the mechanism by which
the fast pathway ERP shortens after slow path-
way ablation, this study prospectively determined
the effect of partial and complete slow pathway
ablation on the ERP of the fast pathway.
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Methods
Patient Population
The subjects consisted of 20 patients with typ-
ical AVNRT that was reproducibly inducible
without pharmacologic intervention during elec-
trophysiologic testing who underwent radiofre-
quency ablation of the slow pathway. The 20
patients consisted of 15 women and 5 men with
a mean age of 43 ± 14 years (± SD). No patient
had structural heart disease. The patients had
been symptomatic for a mean of 17 ± 12 years
and had been treated with a mean of 1.9 ± 1.0
antiarrhythmic medications before the ablation
procedure.
Electrophysiologic Testing
The investigational protocol was approved by
the Committee for Human Research at the Uni-
versity of Michigan and informed consent was
obtained from the patients. Electrophysiologic
tests were performed in the fasting state after all
antiarrhythmic medications had been discontin-
ued for at least 5 half-lives. Three 7-French
quadripolar electrode catheters were inserted into
a femoral vein and positioned in the high right
atrium, across the tricuspid valve to record the
His-bundle electrogram, and in the right ventri-
cle. The catheter across the tricuspid valve had
a 4-mm distal electrode and a deflectable tip
(Mansfield, Watertown, MA, USA) and was also
used for ablation. Leads V,, I, II, and III and
the intracardiac electrograms were displayed on
an oscilloscope and recorded on a Mingograf 7
recorder (Siemens-Elema, Solna, Sweden). After
the catheters were positioned, 3000 units of
heparin was administered intravenously. Pacing
was perfonned with a programmable stimulator
(Bloom Associates, Reading, PA, USA).
The diagnostic portion of the electrophysiologic
test was directed at determining the presence of
dual AV nodal physiology, measuring the con-
duction properties and refractory periods of the fast
and slow AV nodal pathways, and inducing and
determining that the mechanism of the paroxys-
mal supraventricular tachycardia was typical
AVNRT* Incremental pacing and programmed
stimulation were performed in the right atrium and
right ventricle to define anterograde and retrograde
AV nodal conduction and refractoriness and to
confirm that typical AVNRT could be reproducibly
provoked.
Study Protocol
In order to eliminate the possible confounding
effects of changes in sympathetic or vagal tone,
the study protocol was performed during autonomic
blockade. Autonomic blockade was achieved with
intravenous atropine (0.04 mg/kg) and intravenous
propranolol (0.2 mg/kg).'' These drugs were admin-
istered simultaneously over 5 minutes. Five min-
utes later, atrial and ventricular incremental and
programmed stimulation were performed. After
successful elimination of inducible AVNRT with
radiofrequency energy, propranolol and atropine
were administered in doses sufficient to achieve a
sinus cycle length within 20 msec of the preabla-
tion sinus cycle length, and electrophysiologic test-
ing was repeated.
The mean initial doses of atropine and propra-
nolol were 2.9 ± 0.2 and 14.3 ±3.4 mg, respec-
tively. The mean ablation procedure duration was
37 ± 25 minutes. After the abladon procedure, there
were ten patients in whom the sinus cycle length
was within 20 msec of the preablation sinus
cycle length, and, dierefore, administration of addi-
tional atropine or propranolol was not necessary.
Among the other ten patients, a mean of 1.2 ± 0.7
mg of atropine and 5.0 ± 2.2 mg of propranolol
were administered before retesting.
AV nodal echo beats were defined as echo beats
that had a concentric atrial activation sequence,
occurred in association with prolongation of the
AH interval, were reproducible, were simultane-
ous with the QRS complex, and which had a fixed
ventriculoatrial relationship.
After successful ablation of AVNRT, the pres-
ence or absence of residual slow pathway function
was noted. The criteria for residual slow pathway
function consisted of dual AV nodal physiology
and/or AV nodal echo beats after elimination of
inducible AVNRT.
Catheter Ablation Protocol
Radiofrequency energy was delivered by a gen-
erator (EP Technologies, Inc., Sunnyvale, CA,
USA) that supplied a continuous, unmodulated sine
wave output at a frequency of 500 kHz. Suitable
target sites for slow pathway ablation were
identified during sinus rhythm. Mapping was per-
formed in the low posterior right atrium, in the
region of the coronary sinus os. Target sites were
identified by an A:V electrogram ratio < 0.5 and
by the presence of a possible slow pathway poten-
tial or a multicomponent atrial electrogram.^^^
After a target site was identified, radiofrequency
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current was applied at 30 watts for 10 to 30 sec-
onds. The inducibility of AVNRT was assessed
after each application of radiofrequency energy. In
each patient, the inducibility of AVNRT was suc-
cessfully eliminated.
Statistical Analysis
Continuous variables are expressed as mean ±
I SD and were compared using the Student's t-
test for paired or unpaired variables. Nominal vari-
ables were compared by Chi-square analysis. P
values < 0.05 were considered statistically
significant.
Results
After elimination of inducible AVNRT, 7 patients
had evidence of residual slow pathway function
and 13 patients did not (Table 1). Among the seven
patients in whom there was residual slow pathway
function, the mean slow pathway ERP was 243 ±
33 msec before ablation, and 254 ± 36 msec after
ablation (P = 0.10). In the entire cohort of 20
patients, the fast pathway ERP was 319 ± 44 msec
before ablation and 301 ± 54 msec after abladon
(P = 0.05).
In the 13 patients without residual slow path-
way function, the fast pathway ERP shortened
from 334 ± 45 msec before ablation to 300 ± 62
msec after ablation (P < 0.01). In contrast, the
fast pathway ERP in patients who had residual
slow pathway function after ablation did not
change significantly from before ablation (303 ±
38 vs 291 ± 29 msec; P = 0.08). Among the 13
patients without residual slow pathway function,
11 patients demonstrated a 30 msec or more short-
ening of the fast pathway ERP, compared to 0 of
the 7 patients with residual slow pathway func-
tion (P < 0.001).
Discussion
Main Findings
The results of this study demonstrate that
shortening of the fast pathway ERP after slow
pathway ablation is observed only when there
is complete ablation of slow pathway function.
With partial ablation of slow pathway function,
as manifest by persistent AV nodal echoes or
dual AV nodal physiology, shortening of the
fast pathway ERP is not observed. These data
suggest that there may be electrotonic inhibi-
tion of the fast pathway by the slow pathway,
and that loss of this electrotonic effect occurs



































































































































































































































Dual AVN = dual atrioventricular nodal physiology; Echo = AVN echo beat; FP = fast pathway; Pre = preablation; Post =
postablation; SCL = sinus cycle length; SP = slow pathway.
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Comparison to Previous Studies
Successful ablation of AVNRT in this study
was defined as the inability to induce AVNRT,
even if there was evidence of residual slow path-
way function.̂ -s"^ In a previous study evaluating
the effect of slow pathway function on the fast
pathway ERP, the endpoint for ablation was com-
plete elimination of slow pathway function.^ This
prior study reported a shortening of the fast
pathway ERP after complete ablation of slow path-
way function.2 However, because the endpoint for
ablation in that study was the elimination of all
slow pathway function, the effect of incomplete
ablation of the slow pathway could not be deter-
mined. The present study is the first to demon-
strate that shortening of the fast pathway ERP after
elimination of inducible AVNRT is observed when
there is complete ablation of slow pathway func-
tion, but not when residual slow pathway func-
tion persists.
Electrotonus and Other Possible Mechanisms
Electrotonus is a phenomenon in which there is
passive current flow due to voltage gradients
between cells. This passive current flow may
lengthen the refractory period of adjacent cells
by causing subthreshold depolarizations." The pas-
sive cable properties of the tissue determine the
characteristics of the response. After successful
elimination of AVNRT utilizing the slow pathway
approach, electrotonic inhibition of the fast path-
way by the slow pathway could exist only if there
was residual slow pathway function. In this cir-
cumstance, as observed in the present study, the
fast pathway ERP would not be expected to shorten.
With complete ablation of slow pathway function,
electrotonic inhibition of the fast pathway by the
slow pathway would be eliminated, as observed in
this study.
Shortening of the fast pathway ERP after slow
pathway ablation has been proposed to be sec-
ondary to alterations in autonomic tone or loss of
parasympathetic innervation.' Because the data in
the present study were obtained in the setting of
autonomic blockade, shortening of the fast path-
way ERP cannot be explained by changes in sym-
pathetic or parasympathetic tone.
Einally, it is possible that with complete loss
of all slow pathway function after the ablation pro-
cedure, there is some destruction of the most prox-
imal portion of the compact AV node, which does
not occur with incomplete ablation of slow path-
way function. A smaller, compact AV node would
provide a smaller "sink," which could subsequently
contribute to shorter refractory periods. This hypoth-
esis is unlikely, as most effective applications for
elimination of slow pathway function are in the P,
to Pj region,^ and, hence, it would be unlikely that
any portion of the compact AV node would be
destroyed.
Conclusion
Shortening of the fast pathway ERP after
successful elimination of AVNRT is only
observed after complete ablation of slow path-
way function and not after partial ablation of
slow pathway function. This observation is con-
sistent with the hypothesis that there is elec-
trotonic inhibition of the fast pathway by the
slow pathway and that loss of this electro-
tonic effect requires complete elimination of
slow pathway function.
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